Anumana Receives U.S. FDA Breakthrough Device Designation for its Cardiac Amyloidosis Algorithm
Related Articles
Anumana wins FDA breakthrough status for AI algorithm to detect PH
NS Medical Devices: AI-driven health technology company Anumana has received breakthrough device designation from the US Food & Drug Administration (FDA) for its ECG-based Pulmonary Hypertension (PH) algorithm. The AI-enhanced…May 24, 2022
Mayo Clinic launches two tech companies
Modern Healthcare: One of the companies, Anumana, is seeking clearance from the Food and Drug Administration to market an artificial-intelligence tool to detect heart conditions.April 13, 2021
Mayo Clinic, Janssen-backed venture gets FDA OK for pulmonary hypertension AI algorithm
Becker's Hospital Review: A Mayo Clinic and Janssen-backed venture has received FDA breakthrough designation for an algorithm designed to enable early detection of pulmonary hypertension. Anumana Inc. received the breakthrough…May 23, 2022
Migraine with aura identified as independent risk factor for A-fib
Medical Xpress: Patients with migraine with aura (MwA) have significantly higher artificial intelligence-enabled electrocardiogram (AI-ECG) atrial fibrillation (AF) prediction model output, according to a study from Mayo Clinic published online…August 03, 2022